PPI 383

Drug Profile

PPI 383

Alternative Names: PPI-383

Latest Information Update: 08 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Presidio Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 23 Apr 2012 Pharmacodynamics data from in vitro studies in Hepatitis C released by Presidio Pharmaceuticals
  • 11 Jan 2012 PPI 383 is available for licensing. http://www.presidiopharma.com/
  • 09 Jan 2012 Preclinical trials in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top